Autolus Therapeutics plc is a commercial-stage biopharmaceutical company (a U.S.-listed American Depositary Receipt) developing CAR-T (chimeric antigen receptor T-cell) therapies for cancer and autoimmune diseases. Across reputable aggregators, sell-side coverage is predominantly positive, with the stock carrying a "Strong Buy" or "Moderate Buy" consensus and no Hold or Sell ratings among tracked firms.
For this analysis, seven individually attributable, current targets were reviewed: Needham (Gil Blum) at $10, H.C. Wainwright (Emily Bodnar) at $10, Mizuho Securities (Salim Syed) at $10, Leerink Partners at $8, Truist Financial at $8, Goldman Sachs at $5.80, and Wells Fargo at $5. These produce a low-to-high range of about $5 to $10 and a calculated mean near $8.11, rounded to the $8.00 central target used here. Some aggregators show a slightly higher or lower average and a high end near $11, underscoring how sensitive the figure is to which reports are included.
The dispersion is meaningful. The $10 targets generally emphasize the underappreciated value of the obe-cel platform in autoimmune disease, while the $5 to $5.80 targets place more weight on near-term commercial execution and profitability. This spread is not unusual for a pre-profit biotech whose value depends heavily on pipeline data that has not yet read out.
The shares recently traded near $1.32, toward the lower end of a 52-week range of roughly $1.12 to $2.58. Reaching the $8.00 central target would require a gain of about 506%, a very large move that implies a multi-year re-rating rather than an incremental step.
The company's lead product, AUCATZYL (obecabtagene autoleucel, or obe-cel), is an FDA-approved CD19 CAR-T therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). Third-quarter 2026 net product revenue rose roughly 95% year over year to $41.2 million, and full-year 2026 guidance was raised to at or above the upper end of $150 million. Gross margin improved to about 57%, and the U.S. treatment-center network expanded to roughly 90 sites. Even so, the company remains unprofitable on a GAAP (generally accepted accounting principles) basis, and revenue dipped sequentially from the prior quarter, which helps explain why the market price and analyst targets remain far apart.
The stock is trading near multi-month lows and below both its 50-day (around $1.87) and 200-day (around $1.67) moving averages, indicating a prevailing downtrend. The 52-week low near $1.12–$1.20 represents a key support zone, while prior congestion near $1.50–$1.80 and the 52-week high around $2.58 mark notable resistance. A durable recovery toward the $8 target would likely require the shares to first reclaim and hold levels above those moving averages, a structurally significant task given current positioning.
Analyst price targets generally reflect a research horizon of roughly 12 months, though individual firms may differ, and some targets implicitly embed longer-dated pipeline value. Investors should watch quarterly AUCATZYL sales and guidance updates, gross-margin trends, and cash position, as well as clinical data from lupus, lupus nephritis, and amyloidosis programs. Revisions to analyst targets, the delayed multiple sclerosis readout now expected in late 2027, and any changes to the financing picture are the most consequential variables for the gap between the current price and the target.
For traders seeking a data-driven way to monitor changing conditions, Tickeron's AI Daily Buy/Sell Signals apply artificial intelligence to continuously scan thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on evolving market conditions, technical behavior, and AI-driven analysis. The tool is designed to help users surface opportunities, track positions, and identify shifting trends more efficiently than manual review alone. Explore these AI Daily Buy/Sell Signals to complement your own research and stay ahead of changing market dynamics.
The question of whether Autolus Therapeutics can reach $8.00 hinges on the gap between a heavily discounted current valuation and a set of analyst targets that average far above today's price. The calculated mean of seven verified targets is roughly $8.11, but the wide $5-to-$10 range shows that even bullish analysts disagree sharply about how much the autoimmune pipeline and commercial trajectory are worth. Reaching the target would require a roughly 506% advance, a very large move that would likely depend on sustained AUCATZYL growth, continued margin gains, and positive clinical readouts. Persistent losses, a flattening launch curve, and pipeline delays represent the principal obstacles. Investors should monitor earnings, guidance, and clinical catalysts rather than treat the average target as a forecast.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, AUTL has been loosely correlated with CRSP. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if AUTL jumps, then CRSP could also see price increases.
| Ticker / NAME | Correlation To AUTL | 1D Price Change % | ||
|---|---|---|---|---|
| AUTL | 100% | -7.38% | ||
| CRSP - AUTL | 46% Loosely correlated | +0.44% | ||
| SANA - AUTL | 43% Loosely correlated | -8.62% | ||
| EDIT - AUTL | 43% Loosely correlated | -4.09% | ||
| RCKT - AUTL | 43% Loosely correlated | -7.58% | ||
| TSHA - AUTL | 43% Loosely correlated | -1.33% | ||
More | ||||